Russell Investments Group Ltd. Acquires 79,510 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Russell Investments Group Ltd. raised its holdings in Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) by 208.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 117,610 shares of the company’s stock after acquiring an additional 79,510 shares during the quarter. Russell Investments Group Ltd. owned about 0.21% of Health Catalyst worth $1,250,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fairfield Bush & CO. bought a new position in shares of Health Catalyst during the first quarter worth $25,000. Point72 Hong Kong Ltd bought a new position in shares of Health Catalyst during the first quarter worth $33,000. Macquarie Group Ltd. bought a new position in shares of Health Catalyst during the second quarter worth $26,000. US Bancorp DE boosted its position in shares of Health Catalyst by 256.0% during the third quarter. US Bancorp DE now owns 2,645 shares of the company’s stock worth $26,000 after purchasing an additional 1,902 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its position in shares of Health Catalyst by 15,253.3% during the third quarter. Rockefeller Capital Management L.P. now owns 4,606 shares of the company’s stock worth $44,000 after purchasing an additional 4,576 shares in the last quarter. 90.55% of the stock is owned by institutional investors.

Health Catalyst Stock Performance

Shares of Health Catalyst stock opened at $11.05 on Thursday. The company has a 50 day moving average of $11.92 and a 200-day moving average of $11.78. The company has a market cap of $621.67 million, a PE ratio of -4.06 and a beta of 1.23. Health Catalyst, Inc. has a 1-year low of $6.40 and a 1-year high of $18.30. The company has a current ratio of 4.24, a quick ratio of 4.24 and a debt-to-equity ratio of 0.56.

Health Catalyst (NASDAQ:HCAT – Get Rating) last released its quarterly earnings data on Tuesday, February 28th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The business had revenue of $69.16 million during the quarter, compared to analysts’ expectations of $68.37 million. Health Catalyst had a negative net margin of 52.53% and a negative return on equity of 17.45%. As a group, equities research analysts forecast that Health Catalyst, Inc. will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Health Catalyst

In other news, CEO Daniel D. Burton acquired 49,050 shares of Health Catalyst stock in a transaction dated Friday, May 12th. The shares were bought at an average cost of $10.19 per share, with a total value of $499,819.50. Following the purchase, the chief executive officer now owns 919,415 shares in the company, valued at approximately $9,368,838.85. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

HCAT has been the topic of a number of research analyst reports. Guggenheim lowered shares of Health Catalyst from a “buy” rating to a “neutral” rating in a report on Wednesday, May 10th. Citigroup lowered their price target on shares of Health Catalyst from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, March 24th. Royal Bank of Canada lifted their price target on shares of Health Catalyst from $9.00 to $15.00 and gave the company a “sector perform” rating in a research note on Wednesday, March 1st. Raymond James lowered shares of Health Catalyst from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 10th. Finally, Stephens initiated coverage on shares of Health Catalyst in a research note on Tuesday, April 11th. They issued an “equal weight” rating and a $13.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Health Catalyst presently has a consensus rating of “Hold” and an average target price of $15.00.

Health Catalyst Profile

(Get Rating)

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.